| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 |
| filingDate |
2020-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c218a2c3db95288e8dd361308a2b261
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bb07467414b2d14c7651acebe0873aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5c77ab69069ec73f1fb6fe8a7c81b75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a1c21292e37ca5182957f94725e179f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4393413099e96b41cb614a6fbf06c288
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b196d072e478983e0bcd89192f5954c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e8f5efcedf1fb615e6779c63134cfc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4e1ef1484287cc514f8bbdef4ca1712 |
| publicationDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022204527-A1 |
| titleOfInvention |
Fused tricyclic compounds useful as anticancer agents |
| abstract |
The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders. |
| priorityDate |
2019-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |